Articles from Terray Therapeutics

Terray Therapeutics, an AI-native, chemistry-first, biotech today announced its AI and experimental platform, EMMI, and the introduction of advanced Select models that choose the most impactful molecules to make and test in every cycle of drug discovery.

Terray Therapeutics, a chemistry-first, AI-native biotechnology company, today announced the appointment of Wendy Young, Ph.D., to its Board of Directors. Terray integrates AI into every step of small molecule drug discovery, from leveraging Terray’s proprietary dataset of over 10 billion ligand-protein interactions to late-stage multi-parameter optimization, all to design drugs for some of medicine’s toughest challenges.

Terray Therapeutics today announced the appointment of industry veteran Elliott Levy, MD, to the company's Scientific Advisory Board. Terray is a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale. Levy has deep experience in drug development and clinical trials from his roles at Bristol Myers Squibb and Amgen, where he was head of clinical development. He has been involved in the approval of more than 20 new medicines and will work with Terray on the company’s internal small molecule pipeline for autoimmune conditions.

Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, today announced Series B funding of $120 million. The funding will progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova, which it uses to power both internal and partnered programs.